Tech Company Financing Transactions

SRTD biotech Funding Round

Boehringer Ingelheim Venture Fund, Mérieux Equity Partners and NRW.BANK joined a $34.5 million Seed venture round for SRTD biotech. The round was announced on 11/9/2026.

Transaction Overview

Company Name
Announced On
11/9/2026
Transaction Type
Venture Equity
Amount
$34,500,000
Round
Seed
Proceeds Purpose
The company intends to use the funds to advance the preclinical development of its pipeline of novel targeted RNA therapies across oncology, autoimmune, and fibrosis indications towards Investigational New Drug (IND) applications.

Company Information

Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
Huthmacherstrasse 20
Jülich, 52428
Germany
Phone
Undisclosed
Email Address
Overview
We are developing the first pro-drug platform on RNA level, targeting oncological, viral and genetic diseases. It is our mission to open a new chapter in treating diseases and to deliver so called selectively expressed RNAs (seRNAs) to patients. We have an ambitious pipeline that targets indications of highest medical need. Many devastating diseases cannot be effectively treated. Even if therapies exist, often they don't specifically target the diseased area, leading to a high risk of severe side effects. To overcome this inherent problem, we have developed seRNA as a new RNA-based therapy approach.
Profile
SRTD biotech LinkedIn Company Profile
Social Media
SRTD biotech Company Twitter Account
Company News
SRTD biotech News
Facebook
SRTD biotech on Facebook
YouTube
SRTD biotech on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Bernd Hoffmann
  Bernd Hoffmann LinkedIn Profile  Bernd Hoffmann Twitter Account  Bernd Hoffmann News  Bernd Hoffmann on Facebook
Chief Financial Officer
Georg Lautscham
  Georg Lautscham LinkedIn Profile  Georg Lautscham Twitter Account  Georg Lautscham News  Georg Lautscham on Facebook


 

 

Browse more venture capital transactions:

Prev: 11/9/2026: Onodrim Industries venture capital transaction
Next: 11/9/2026: Atea Pharmaceuticals venture capital transaction

 

Share this article

 


Where The Data Comes From

We do our best to document every notable VC transaction. VC investment data records on this site are derived from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary